| 1 |
Dai Y, Zhao W, Yue L, Dai X, Rong D, Wu F, Gu J, Qian X. Perspectives on Immunotherapy of Metastatic Colorectal Cancer. Front Oncol 2021;11:659964. [PMID: 34178645 DOI: 10.3389/fonc.2021.659964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 2 |
Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, Currò G, Ammendola M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J Clin Med 2020;9:E2852. [PMID: 32899322 DOI: 10.3390/jcm9092852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
He R, Zhang M, He L, Huang J, Man C, Wang X, Lang Y, Fan Y. Integrated Analysis of Necroptosis-Related Genes for Prognosis, Immune Microenvironment Infiltration, and Drug Sensitivity in Colon Cancer. Front Med 2022;9:845271. [DOI: 10.3389/fmed.2022.845271] [Reference Citation Analysis]
|
| 4 |
Jin H, Amonkar M, Aguiar-Ibáñez R, Thosar M, Chase M, Keeping S. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair-deficient colorectal cancer. Future Oncol 2022. [PMID: 35332802 DOI: 10.2217/fon-2021-1633] [Reference Citation Analysis]
|
| 5 |
Saleh K, Kordahi M, Felefly T, Khalife N. Pembrolizumab: a new standard of care in metastatic colorectal cancer. Immunotherapy 2021;13:1245-7. [PMID: 34542319 DOI: 10.2217/imt-2021-0051] [Reference Citation Analysis]
|
| 6 |
Yi X, Hu C, Zhang C, Shao K, Sun H, Jiang Y, Sun N, Zhi X. KIAA1522 is a new biomarker of promoting the tumorigenesis and distant metastasis of colorectal carcinoma. Cell Signal 2022;90:110202. [PMID: 34826587 DOI: 10.1016/j.cellsig.2021.110202] [Reference Citation Analysis]
|
| 7 |
Galindo-Pumariño C, Collado M, Herrera M, Peña C. Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. Cancers (Basel) 2021;13:1130. [PMID: 33800796 DOI: 10.3390/cancers13051130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Brovkina OI, Nikitin AG. KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection. Journal of Clinical Practice 2021;12:66-71. [DOI: 10.17816/clinpract63875] [Reference Citation Analysis]
|
